Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention

Neurobiology of Disease

Volumn 37, Issue 3, 2010, Pages 510-518

  Tansey, Malú G ^a   Goldberg, Matthew S ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Inflammation; Microglia; Neurodegeneration; Neuroinflammation; Parkinson's disease

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; ALPHA SYNUCLEIN; CYCLOSPORIN A; DEXAMETHASONE; DEXTROMETHORPHAN; GAMMA INTERFERON; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; N(G) NITROARGININE; NEUROIMMUNOPHILIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARGYLINE; PARKIN; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN E2; PROSTAGLANDIN J2; PROTEIN P53; RGS PROTEIN; RGS10 PROTEIN; SALICYLATE SODIUM; SELEGILINE; SILYMARIN; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL SURVIVAL; CHRONIC INFLAMMATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; GASTROINTESTINAL INFECTION; GLIA CELL; HEREDITY; HUMAN; IMMUNOMODULATION; INFECTION; MESENCEPHALON; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SUBSTANTIA NIGRA; VIRUS ENCEPHALITIS;

CYTOPROTECTION; ENCEPHALITIS; ENVIRONMENT; IMMUNOLOGIC FACTORS; MICROGLIA; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 75949087271     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.11.004     Document Type: Review

References (137)

1. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv. Exp. Med. Biol. 468 (1999) 123-133
2. Aloisi F. Immune function of microglia. Glia 36 (2001) 165-179
3. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., and Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J. Biol. Chem. 279 (2004) 51647-51653
4. Arai H., Furuya T., Mizuno Y., and Mochizuki H. Inflammation and infection in Parkinson's disease. Histol. Histopathol. 21 (2006) 673-678
5. Arimoto T., and Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 12 (2003) 35-45
6. Banati R.B., Daniel S.E., and Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13 (1998) 221-227
7. Barcia C., Fernandez Barreiro A., Poza M., and Herrero M.T. Parkinson's disease and inflammatory changes. Neurotox. Res. 5 (2003) 411-418
8. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., Brant S.R., Silverberg M.S., Taylor K.D., Barmada M.M., Bitton A., Dassopoulos T., Datta L.W., Green T., Griffiths A.M., Kistner E.O., Murtha M.T., Regueiro M.D., Rotter J.I., Schumm L.P., Steinhart A.H., Targan S.R., Xavier R.J., Libioulle C., Sandor C., Lathrop M., Belaiche J., Dewit O., Gut I., Heath S., Laukens D., Mni M., Rutgeerts P., Van Gossum A., Zelenika D., Franchimont D., Hugot J.P., de Vos M., Vermeire S., Louis E., Cardon L.R., Anderson C.A., Drummond H., Nimmo E., Ahmad T., Prescott N.J., Onnie C.M., Fisher S.A., Marchini J., Ghori J., Bumpstead S., Gwilliam R., Tremelling M., Deloukas P., Mansfield J., Jewell D., Satsangi J., Mathew C.G., Parkes M., Georges M., and Daly M.J. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40 (2008) 955-962
9. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
10. Benner E.J., Banerjee R., Reynolds A.D., Sherman S., Pisarev V.M., Tsiperson V., Nemachek C., Ciborowski P., Przedborski S., Mosley R.L., and Gendelman H.E. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3 (2008) e1376
11. Bialecka M., Kurzawski M., Klodowska-Duda G., Opala G., Juzwiak S., Kurzawski G., Tan E.K., and Drozdzik M. CARD15 variants in patients with sporadic Parkinson's disease. Neurosci. Res. 57 (2007) 473-476
12. Block M.L., and Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76 (2005) 77-98
13. Block M.L., Zecca L., and Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev., Neurosci. 8 (2007) 57-69
14. Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem. Res. 32 (2007) 1700-1708
15. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
16. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.M., Duyckaerts C., Flavell R.A., Hirsch E.C., and Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119 (2009) 182-192
17. Bronstein D.M., Perez-Otano I., Sun V., Mullis Sawin S.B., Chan J., Wu G.C., Hudson P.M., Kong L.Y., Hong J.S., and McMillian M.K. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704 (1995) 112-116
18. Camandola S., and Mattson M.P. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin. Ther. Targets 11 (2007) 123-132
19. Carvey P.M., Chang Q., Lipton J.W., and Ling Z. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front. Biosci. 8 (2003) s826-837
20. Casals J., Elizan T.S., and Yahr M.D. Postencephalitic parkinsonism - a review. J. Neural Transm. 105 (1998) 645-676
21. Castano A., Herrera A.J., Cano J., and Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70 (1998) 1584-1592
22. Castano A., Herrera A.J., Cano J., and Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem. 81 (2002) 150-157
23. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059-1064
24. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk of Parkinson's disease. Ann. Neurol. 59 (2005) 988-989
25. Chen H., O'Reilly E.J., Schwarzschild M.A., and Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 167 (2008) 90-95
26. Chung C.Y., Seo H., Sonntag K.C., Brooks A., Lin L., and Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 14 (2005) 1709-1725
27. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., and Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5 (1996) 137-143
28. Dale R.C., Church A.J., Surtees R.A., Lees A.J., Adcock J.E., Harding B., Neville B.G., and Giovannoni G. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 127 (2004) 21-33
29. De Pablos R.M., Herrera A.J., Villaran R.F., Cano J., and Machado A. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J. 19 (2005) 407-409
30. Delgado M., and Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 17 (2003) 1922-1924
31. Delgado M., and Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 17 (2003) 944-946
32. Diguet E., Fernagut P.O., Wei X., Du Y., Rouland R., Gross C., Bezard E., and Tison F. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci. 19 (2004) 3266-3276
33. Dilger R.N., and Johnson R.W. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J. Leukoc. Biol. 84 (2008) 932-939
34. Dobbs R.J., Charlett A., Dobbs S.M., Weller C., and Peterson D.W. Parkinsonism: differential age-trend in Helicobacter pylori antibody. Aliment. Pharmacol. Ther. 14 (2000) 1199-1205
35. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., and Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14669-14674
36. Duke D.C., Moran L.B., Pearce R.K., and Graeber M.B. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 8 (2007) 83-94
37. Dutta G., Zhang P., and Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol. 22 (2008) 453-464
38. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205 (2007) 295-312
39. Frank-Cannon T.C., Tran T., Ruhn K.A., Martinez T.N., Hong J., Marvin M., Hartley M., Trevino I., O'Brien D.E., Casey B., Goldberg M.S., and Tansey M.G. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 28 (2008) 10825-10834
40. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., and Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002) 1285-1297
41. Gao H.M., Hong J.S., Zhang W., and Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J. Neurosci. 23 (2003) 1228-1236
42. Gao H.M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., and Lee V.M. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28 (2008) 7687-7698
43. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., and Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 133 (2002) 27-35
44. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56 (1999) 33-39
45. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., and Brooks D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21 (2006) 404-412
46. German D.C., Speciale S.G., Manaye K.F., and Sadeq M. Opioid receptors in midbrain dopaminergic regions of the rat. I. Mu receptor autoradiography. J. Neural Transm. Gen. Sect. 91 (1993) 39-52
47. Ghosh A., Roy A., Liu X., Kordower J.H., Mufson E.J., Hartley D.M., Ghosh S., Mosley R.L., Gendelman H.E., and Pahan K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U S A 104 (2007) 18754-18759
48. Gold B.G., and Nutt J.G. Neuroimmunophilin ligands in the treatment of Parkinson's disease. Curr. Opin. Pharmacol. 2 (2002) 82-86
49. Goldberg M.S., and Lansbury Jr. P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2 (2000) E115-119
50. Golde T.E. The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. Mol. Neurodegener. 4 (2009) 8
51. Goldman S.M., Tanner C.M., Oakes D., Bhudhikanok G.S., Gupta A., and Langston J.W. Head injury and Parkinson's disease risk in twins. Ann. Neurol. 60 (2006) 65-72
52. Hamaue N., Ogata A., Terado M., Ohno K., Kikuchi S., Sasaki H., Tashiro K., Hirafuji M., and Minami M. Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus. Neurochem. Res. 31 (2006) 1451-1455
53. Hancock D.B., Martin E.R., Stajich J.M., Jewett R., Stacy M.A., Scott B.L., Vance J.M., and Scott W.K. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch. Neurol. 64 (2007) 576-580
54. He Y., Appel S., and Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909 (2001) 187-193
55. Hemmer K., Fransen L., Vanderstichele H., Vanmechelen E., and Heuschling P. An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. Neurochem. Int. 38 (2001) 557-565
56. Henry C.J., Huang Y., Wynne A.M., and Godbout J.P. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain. Behav. Immun. 23 (2009) 309-317
57. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-1099
58. Herrera A.J., Castano A., Venero J.L., Cano J., and Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7 (2000) 429-447
59. Hirsch E.C., and Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 8 (2009) 382-397
60. Hirsch E.C., Hunot S., and Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 11 Suppl 1 (2005) S9-S15
61. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., and Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
62. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., and Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7531-7536
63. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., and Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 3440-3447
64. Iravani M.M., Kashefi K., Mander P., Rose S., and Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110 (2002) 49-58
65. Jang H., Boltz D., Sturm-Ramirez K., Shepherd K.R., Jiao Y., Webster R., and Smeyne R.J. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 14063-14068
66. Josephs K.A., Parisi J.E., and Dickson D.W. Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology 59 (2002) 645-646
67. Kaltschmidt B., Widera D., and Kaltschmidt C. Signaling via NF-kappaB in the nervous system. Biochim. Biophys. Acta 1745 (2005) 287-299
68. Kamel F., Tanner C., Umbach D., Hoppin J., Alavanja M., Blair A., Comyns K., Goldman S., Korell M., Langston J., Ross G., and Sandler D. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am. J. Epidemiol. 165 (2007) 364-374
69. Kim S.U., and de Vellis J. Microglia in health and disease. J. Neurosci. Res. 81 (2005) 302-313
70. Kim H.S., and Suh Y.H. Minocycline and neurodegenerative diseases. Behav. Brain Res. 196 (2009) 168-179
71. Klegeris A., and McGeer P.L. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol. 166 (2000) 458-464
72. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998) 167-180
73. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., and Hendrikse N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57 (2005) 176-179
74. Kurkowska-Jastrzebska I., Litwin T., Joniec I., Ciesielska A., Przybylkowski A., Czlonkowski A., and Czlonkowska A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 4 (2004) 1307-1318
75. Laurie C., Reynolds A., Coskun O., Bowman E., Gendelman H.E., and Mosley R.L. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 183 (2007) 60-68
76. Lawrence T., Gilroy D.W., Colville-Nash P.R., and Willoughby D.A. Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 7 (2001) 1291-1297
77. Lawson L.J., Perry V.H., Dri P., and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39 (1990) 151-170
78. Le W., Rowe D., Xie W., Ortiz I., He Y., and Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21 (2001) 8447-8455
79. Lee J.K., McCoy M.K., Harms A.S., Ruhn K.A., Gold S.J., and Tansey M.G. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J. Neurosci. 28 (2008) 8517-8528
80. Lees A.J., Hardy J., and Revesz T. Parkinson's disease. Lancet 373 (2009) 2055-2066
81. Liang Z.Q., Li Y.L., Zhao X.L., Han R., Wang X.X., Wang Y., Chase T.N., Bennett M.C., and Qin Z.H. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res. 1145 (2007) 190-203
82. Lim K.L., and Ng C.H. Genetic models of Parkinson disease. Biochim. Biophys. Acta 1792 (2009) 604-615
83. Ling Z., Gayle D.A., Ma S.Y., Lipton J.W., Tong C.W., Hong J.S., and Carvey P.M. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov. Disord. 17 (2002) 116-124
84. Ling Z., Zhu Y., Tong C., Snyder J.A., Lipton J.W., and Carvey P.M. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp. Neurol. 199 (2006) 499-512
85. Ling Z., Zhu Y., Tong C.W., Snyder J.A., Lipton J.W., and Carvey P.M. Prenatal lipopolysaccharide does not accelerate progressive dopamine neuron loss in the rat as a result of normal aging. Exp. Neurol. 216 (2009) 312-320
86. Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304 (2003) 1-7
87. Liu B., Gao H.M., and Hong J.S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Perspect. 111 (2003) 1065-1073
88. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., and Hong J.S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 305 (2003) 212-218
89. Marchetti B., and Abbracchio M.P. To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol. Sci. 26 (2005) 517-525
90. Mattson M.P. NF-kappaB in the survival and plasticity of neurons. Neurochem. Res. 30 (2005) 883-893
91. Mattson M.P., and Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 13 (2006) 852-860
92. McCoy M.K., Martinez T.N., Ruhn K.A., Szymkowski D.E., Smith C.G., Botterman B.R., Tansey K.E., and Tansey M.G. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 26 (2006) 9365-9375
93. McGeer E.G., and McGeer P.L. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 33 (1998) 371-378
94. McGeer P.L., and McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 12 Suppl 2 (1998) S1-S6
95. McGeer E.G., and McGeer P.L. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 21 (2007) 789-797
96. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
97. McGeer E.G., Klegeris A., and McGeer P.L. Inflammation, the complement system and the diseases of aging. Neurobiol. Aging 26 Suppl 1 (2005) 94-97
98. McGuire S.O., Ling Z.D., Lipton J.W., Sortwell C.E., Collier T.J., and Carvey P.M. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169 (2001) 219-230
99. Minghetti L., Ajmone-Cat M.A., De Berardinis M.A., and De Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res. Brain Res. Rev. 48 (2005) 251-256
100. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994) 208-210
101. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., and Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211 (1996) 13-16
102. Mogi M., Togari A., Tanaka K., Ogawa N., Ichinose H., and Nagatsu T. Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci. Lett. 289 (2000) 165-168
103. Nagatsu T., Mogi M., Ichinose H., and Togari A. Cytokines in Parkinson's disease. J. Neural Transm. Suppl. (2000) 143-151
104. Nimmo A.J., and Vink R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat. CNS Drug Discov. 4 (2009) 86-95
105. Ogata A., Tashiro K., Nukuzuma S., Nagashima K., and Hall W.W. A rat model of Parkinson's disease induced by Japanese encephalitis virus. J. Neurovirol. 3 (1997) 141-147
106. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., and Cho J.H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
107. Pierre S.R., Lemmens M.A., and Figueiredo-Pereira M.E. Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J. Neuroinflammation 6 (2009) 18
108. Pizzi M., and Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur. J. Pharmacol. 545 (2006) 22-28
109. Przuntek H., Muller T., and Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J. Neural Transm. 111 (2004) 201-216
110. Reynolds A.D., Stone D.K., Mosley R.L., and Gendelman H.E. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J. Immunol. 182 (2009) 4137-4149
111. Samii A., Etminan M., Wiens M.O., and Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 26 (2009) 769-779
112. Sanchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A.L., and Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation 1 (2004) 6
113. Schapira A.H. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol. Sci. 30 (2009) 41-47
114. Schapira A.H. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 72 (2009) S44-50
115. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
116. Shoji H., Watanabe M., Itoh S., Kuwahara H., and Hattori F. Japanese encephalitis and parkinsonism. J. Neurol. 240 (1993) 59-60
117. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. Faseb J 20 (2006) 670-682
118. Streit W.J. Microglial response to brain injury: a brief synopsis. Toxicol. Pathol. 28 (2000) 28-30
119. Tang B.L., and Liou Y.C. Novel modulators of amyloid-beta precursor protein processing. J. Neurochem. 100 (2007) 314-323
120. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5473-5478
121. The National Institute of Neurological Disorders and Stroke Neuroprotective Exploratory Trials in Parkinson's Disease Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. 10.1212/01.wnl.0000201252.57661.e1. Neurology 66 (2006) 664-671
122. Theodore S., Cao S., McLean P.J., and Standaert D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67 (2008) 1149-1158
123. Thiruchelvam M., Richfield E.K., Goodman B.M., Baggs R.B., and Cory-Slechta D.A. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23 (2002) 621-633
124. Thorsen P., Jensen I.P., Jeune B., Ebbesen N., Arpi M., Bremmelgaard A., and Moller B.R. Few microorganisms associated with bacterial vaginosis may constitute the pathologic core: a population-based microbiologic study among 3596 pregnant women. Am. J. Obstet. Gynecol. 178 (1998) 580-587
125. Tomas-Camardiel M., Rite I., Herrera A.J., de Pablos R.M., Cano J., Machado A., and Venero J.L. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 16 (2004) 190-201
126. Tran T.A., McCoy M.K., Sporn M.B., and Tansey M.G. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J. Neuroinflammation 5 (2008) 14
127. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., and Jeng K.C. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. Neurosci. 16 (2002) 2103-2112
128. Weller C., Oxlade N., Dobbs S.M., Dobbs R.J., Charlett A., and Bjarnason I.T. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol. Med. Microbiol. 44 (2005) 129-135
129. Weller C., Charlett A., Oxlade N.L., Dobbs S.M., Dobbs R.J., Peterson D.W., and Bjarnason I.T. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism: Part 3. Predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 10 (2005) 288-297
130. Wersinger C., and Sidhu A. Inflammation and Parkinson's disease. Curr. Drug Targets Inflamm. Allergy 1 (2002) 221-242
131. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 (2007) 963-976
132. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
133. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 12 (2006) 1005-1015
134. Wyss-Coray T., and Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 35 (2002) 419-432
135. Yang L., Sugama S., Chirichigno J.W., Gregorio J., Lorenzl S., Shin D.H., Browne S.E., Shimizu Y., Joh T.H., Beal M.F., and Albers D.S. Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74 (2003) 278-285
136. Yang L., Calingasan N.Y., Thomas B., Chaturvedi R.K., Kiaei M., Wille E.J., Liby K.T., Williams C., Royce D., Risingsong R., Musiek E.S., Morrow J.D., Sporn M., and Beal M.F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One 4 (2009) e5757
137. Zhou Y., Su Y., Li B., Liu F., Ryder J.W., Wu X., Gonzalez-DeWhitt P.A., Gelfanova V., Hale J.E., May P.C., Paul S.M., and Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302 (2003) 1215-1217